Nymox Pharmaceutical Corporation Update on Nymozarfex Approval

Nymox Pharmaceutical Corporation has announced its current focus on re-submitting Nymozarfex for marketing approval in the US. The initial US submission was not accepted for review. In Europe, submissions to Denmark and UK agencies were accepted for review but initially refused. The company is considering updated re-submissions, citing confidence in their clinical data.

The skepticism from reviewers centers around the one-year placebo effect persistence, despite evidence from broader literature, and the practical benefits of long-term efficacy in BPH. Nymox's CEO highlighted financial constraints as a challenge for resubmissions and emphasized the strong public demand for effective BPH treatments.

The company is seeking additional financing to support future re-submissions. The CEO remains confident in the treatment's prospects, citing robust Phase 3 data. Despite the challenges, Nymox continues to aim for making the treatment available to patients.